Gilead Sciences

This is an early-stage study to find a safe dose and understand the side effects of a new drug called GS-5319. It is for adults with advanced solid tumors that have stopped responding to standard treatments and have a specific genetic alteration called MTAP-deletion. The main goa…

This study is testing several new drug combinations for different types of lung cancer. It will enroll 270 participants across three groups: those with newly diagnosed advanced cancer, those whose cancer has progressed after treatment, and those with cancer that can be surgically…

This program provides access to an investigational drug called bulevirtide for people with chronic hepatitis D virus infection who have compensated liver cirrhosis. It is for eligible patients who meet specific medical criteria. The goal is to offer a treatment option to manage t…

This study is testing a new combination of two HIV drugs, bictegravir and lenacapavir, in children and adolescents who already have their HIV under control with other medications. Researchers want to see how the body processes these drugs, find the right dose for kids, and check …

This is a first-in-human study to test the safety and find the right dose of a new immunotherapy drug called denikitug. It is being tested alone and in combination with another immunotherapy drug in adults with advanced solid tumors that have not responded to standard treatments.…

This study aims to test the safety and effectiveness of a medication called tenofovir alafenamide (TAF) for children and teenagers with chronic hepatitis B. It will enroll 150 participants to compare the drug against a placebo for 24 weeks, followed by longer-term monitoring. The…

This study is testing a drug called sacituzumab govitecan, both by itself and combined with other treatments, for people with advanced bladder cancer that has spread and cannot be removed by surgery. The main goals are to see if the treatment shrinks tumors and is safe for patien…

This study is testing whether an experimental drug called tilpisertib fosmecarbil (GS-5290) can help control symptoms of moderate to severe ulcerative colitis. About 176 adults who haven't responded well to other treatments will receive either the drug or a placebo for 12 weeks. …

This study is testing a new drug called GS-4321 for people with chronic hepatitis delta, a serious liver infection. First, researchers will check the drug's safety and how it moves through the body in healthy volunteers. Then, they will give it to people with the disease to see i…

This is an early-stage study to check the safety and initial antiviral effect of a new HIV medication called GS-3242. It will involve about 30 adults living with HIV who are not currently on treatment. Researchers will measure how the drug affects the amount of virus in the blood…

This early-stage study aims to test the safety and side effects of a new drug called GS-0151 in adults with rheumatoid arthritis. Researchers will give different doses to 75 participants to see how their bodies handle the medication and monitor for any problems. The study will al…

This study is testing a different dose and schedule for the drug sacituzumab govitecan in people with advanced triple-negative breast cancer. The main goals are to see if this new schedule is safe and if it helps shrink tumors or delay cancer growth. The study will enroll about 1…

This is an early-stage study to test a new oral drug called GS-4571 for weight management. Researchers will give the drug to healthy people, people with obesity, and people with type 2 diabetes to see how their bodies process it and to check for side effects. The main goal is to …

This study is testing a long-acting HIV medicine called lenacapavir in children and teenagers who have been treated before and whose current medicines are not fully working. Researchers want to see if the drug is safe, how it behaves in the body, and if it helps control the virus…

This study is testing whether a new two-drug combination given after surgery works better and is safer than standard treatments for people with triple-negative breast cancer that didn't fully disappear with initial therapy. It will involve about 1,500 participants who still have …

This study is testing whether a drug called seladelpar can help prevent serious liver problems in people with primary biliary cholangitis (PBC) who have early-stage scarring (cirrhosis). About 318 participants will be randomly assigned to receive either the study drug or a placeb…

This study is testing whether a newer drug, sacituzumab govitecan, works better than the current standard treatments for people with extensive stage small cell lung cancer that has worsened after their first round of chemotherapy. About 695 participants will be randomly assigned …

This study provides continued access to HIV medications for children and adolescents who have successfully completed an earlier Gilead HIV treatment trial. Its main purpose is to allow these young participants to keep receiving their effective treatment while researchers monitor …

This early-stage study aims to find a safe starting dose of the cancer drug sacituzumab govitecan for people with advanced solid tumors who also have moderate liver problems. Researchers will enroll 30 participants to carefully monitor how the drug behaves in their bodies and wha…

This study is testing a new drug called lenacapavir, given as a single injection once a year, to see if it can safely prevent HIV infection in people who are at risk. The main goals are to measure how much of the drug stays in the body over a year and to check for any side effect…

This study aims to find a safe dose of a three-drug combination pill (B/F/TAF) to prevent HIV infection in newborns whose mothers have HIV. It will enroll 16 full-term, uninfected newborns to check for side effects and measure how the drug moves through their bodies. The goal is …